Piroxicam-induced photodermatitis. Cross-reactivity among oxicams. A case report

Trujillo, M J; Barrio, M. De; Rodríguez, A.; Moreno-Zazo, M; Sánchez, Isabel; Pelta, R.; Tornero, Pilar; Herrero, T.

doi:10.1016/s0301-0546(01)79046-5

Cited by 30 publications

(7 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…But there was no cross-reaction with tenoxicam and lenoxicam and only 1/31 had positive photopatch tests with meloxicam. In contrast, in 1 case with a photosensitization to piroxicam, all photopatch tests done with piroxicam, tenoxicam, droxicam and meloxicam were positive [122] . However, in 8 patients with FDE, cross-reactions between oxicams were very frequent [123] .…”

Section: Usefulness Of Drug Skin Tests To Study Cross-reactivity Betwmentioning

confidence: 80%

Place of Drug Skin Tests in Investigating Systemic Cutaneous Drug Reactions

Barbaud¹

2007

Drug Hypersensitivity

View full text Add to dashboard Cite

Skin tests with drugs can be helpful in determining the cause of cutaneous adverse drug reactions (CADR). Patch tests and prick tests can be done with any commercialized form of a drug, intradermal tests (IDT) normally rely on the availability of a sterile solution used for parental applications. There has been some experience with different concentrations and techniques, but a complete standardization has not been done with these tests. Prick tests and IDT are used to investigate immediate hypersensitivity, patch tests and IDT with delayed readings are helpful for symptoms appearing delayed. They can be positive in different skin symptoms, with or without involvement of internal organs (e.g. hepatitis). A great variety of drugs can be tested, including antibiotics, antiepileptics, drugs used in oncology, drugs used for diagnosis etc. Except for IDT, skin tests with drugs rarely induce adverse reactions. False positive results can occur and should be considered, if a product for skin tests is evaluated for the first time. The negative predictive value of skin tests with drugs is a crucial point that will have to be studied in detail in the near future.

show abstract

Section: Usefulness Of Drug Skin Tests To Study Cross-reactivity Betwmentioning

confidence: 80%

Place of Drug Skin Tests in Investigating Systemic Cutaneous Drug Reactions

Barbaud¹

2007

Drug Hypersensitivity

View full text Add to dashboard Cite

show abstract

“…Some reports have described dyshidrosiform dermatitis associated with photoallergic eruption in patients who had received oral piroxicam, but no one previously has reported dyshidrosiform dermatitis alone (3–6).…”

Section: Discussionmentioning

confidence: 99%

Oral piroxicam‐induced dyshidrosiform dermatitis

Piqué¹,

Pérez²,

Benjumeda³

2004

Contact Dermatitis

View full text Add to dashboard Cite

“…The pathophysiological mechanisms are not fully explained, but it is suggested that the NSAIDs could act as a hapten, binding to a protein bound to melanocytes, and producing a specific cytotoxic reaction directed at the melanocytes bound by the hapten. The drugs most frequently associated with this adverse reaction are paracetamol, salicylates, derivatives of oxicam, and ibuprofen [42][43][44][45] (Figure 4).…”

Section: Nonsteroidal Anti-inflammatory Drugsmentioning

confidence: 99%

Drug-Induced Hyperpigmentation: Review and Case Series

García

Carrasco-Molina

2019

J Am Board Fam Med

View full text Add to dashboard Cite

Background: Hyperpigmentation is a common dermatologic problem that may have substantial impact on the patient, since it affects the appearance and quality of life, and may influence treatment adherence. There are few studies of drug-induced hyperpigmentation. Methods: We studied drug-induced hyperpigmentation in patients attending an outpatient dermatology clinic in the Western Area of Valladolid (Spain) from August 1, 2017 to April 20, 2018. Results: The incidence of drug-induced hyperpigmentation was 1.31% in patients attending a first dermatology consultation in the study period. Of the 16 patients, 8 were taking more than 1 drug. The most frequent drugs identified were nonsteroidal anti-inflammatory agents (25%), antihypertensive agents (18.75%), antimalarials (12.5%), antibiotics, antineoplastic agents, psychoactive agents, simvastatin, allopurinol, amiodarone and mucolytic (6.25% each). Hyperpigmentation was found in the mucosa in 25% of patients and in photograph-exposed areas in 37.5%. Discussion: Diagnosing drug-induced hyperpigmentation is a dermatologic challenge. A differential diagnosis with hyperpigmentation caused by endocrine and metabolic disorders, the most closely-related disorders to drug-induced hyperpigmentation, and with hyperpigmentation of idiopathic origin, should be conducted. Drug-induced hyperpigmentation is a relatively frequent reason for consultation, especially in polypharmacy patients. The sample may have been biased as many patients receiving treatments frequently associated with drug-induced hyperpigmentation, such as antineoplastic drugs, are diagnosed and treated by other specialties, such as oncologists. Conclusion: Family physicians and specialists should consider drugs as a cause of hyperpigmentation to facilitate the correct diagnosis and treatment.

show abstract

Piroxicam-induced photodermatitis. Cross-reactivity among oxicams. A case report

Cited by 30 publications

References 11 publications

Place of Drug Skin Tests in Investigating Systemic Cutaneous Drug Reactions

Place of Drug Skin Tests in Investigating Systemic Cutaneous Drug Reactions

Oral piroxicam‐induced dyshidrosiform dermatitis

Drug-Induced Hyperpigmentation: Review and Case Series

Contact Info

Product

Resources

About